CON vs PAIYY Stock Comparison

Concentra Group Holdings Parent and Aesthetic Medical International Holdings Prices as of Oct 26, 2026 Peers: Industry group

Head to Head

3 decided of 12

Concentra Group Holdings Parent leads on 3 of the 12 questions below (Concentra Group Holdings Parent 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCONPAIYYLeader
Larger companyMarket capitalisation $5.00B $491.09K CON
Cheaper on earningsLower P/E, profitable companies only 25.2x -0.1x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 23.4x — –
Faster revenue growthRevenue growth, trailing twelve months +14.0% — –
More profitableNet margin, trailing twelve months 8.7% — –
Better return on capitalReturn on invested capital 14.2% — –
Less leveragedLower net debt / EBITDA 3.1x — –
Higher dividend yieldTrailing dividend yield 0.01% — –
Better 1-year returnPrice return, last 12 months +92.3% -95.2% CON
Better 5-year returnAnnualised price return, 5 years — -70.1%/yr –
Less volatileAnnualised volatility, 1 year 27.9% 421.9% CON
Higher overall scoreMean of the five percentile scores vs peers 57/100 — –

Percentile Scorecard

CONPAIYY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCONPAIYY
Valuation 59 #39 of 93 22 #73 of 93
Growth 64 #32 of 88 –
Profitability 86 #13 of 87 –
Financial Health 27 #73 of 100 11 #89 of 100
Shareholder Returns 51 #28 of 56 –
Overall 57 –
  • CON ranked among 103 companies in Healthcare Providers
  • PAIYY ranked among 103 companies in Healthcare Providers

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCONPAIYYSPY
1 month +14.9%-50.0% -0.8%
3 months +26.0%-50.0% +3.5%
6 months +77.4%-88.9% +7.0%
Year to date +104.4%-94.1% +12.2%
1 year +92.3%-95.2% +13.0%
3 years —-98.4% +86.3%
3 years, per year —-74.9% +23.1%
5 years —-99.8% +68.6%
5 years, per year —-70.1% +11.0%

Risk

MeasureCONPAIYYSPY
Volatility, 1Y 27.9%421.9% 12.7%
Downside volatility, 1Y 23.2%1,222.1% 12.7%
Beta vs S&P 500, 1Y 0.42-3.71 1.00
Return / volatility, 1Y 3.31-0.23 1.02
Max drawdown, 5Y -23.5%-99.8% -25.4%
From 52-week high 0.0%-96.9% -1.8%
52-week high $40.22$0.32 $779.14
52-week low $18.71$0.01 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCONPAIYY
P/E now vs peer median 25.3xmedian 25.1x -0.1xmedian 25.1x
P/S now vs peer median 2.2xmedian 1.6x 0.0xmedian 1.6x
EV/EBITDA now vs peer median 14.3xmedian 14.5x —median 14.5x
P/FCF now vs peer median 19.2xmedian 22.4x -0.2xmedian 22.4x
P/B now vs peer median 10.6xmedian 3.1x -0.1xmedian 3.1x
PEG now vs peer median —median 0.66 —median 0.66

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCONPAIYY
Revenue $2.29B –
Gross profit $670.56M –
Operating income $374.81M –
Net income $203.80M –
Free cash flow $267.42M –
EPS (diluted) $1.56 –
Cash & equivalents $158.04M $8.61M
Total debt $1.57B $76.21M
Shares (diluted) 127.79M 47.83M
Enterprise value $4.65B -$24.51M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCONPAIYY
P/E 25.3x -0.1x
P/FCF 19.2x -0.2x
P/Operating cash flow 15.3x –
P/S 2.2x 0.0x
P/B 10.6x -0.1x
P/Tangible book 20.3x -0.1x
EV/EBITDA 14.3x –
EV/EBIT 17.5x –
EV/Revenue 2.9x –
EV/FCF 24.5x –
EV/Operating cash flow 19.5x –
PEG (3Y EPS CAGR) – –

Growth

14 metrics
MetricCONPAIYY
Revenue growth (1Y) 14.0% –
Revenue CAGR (3Y) – –
Gross profit growth (1Y) 18.9% –
Gross profit CAGR (3Y) – –
Operating income growth (1Y) 18.9% –
Operating income CAGR (3Y) – –
Net income growth (1Y) 32.6% –
Net income CAGR (3Y) – –
EPS growth (1Y) 33.5% –
EPS CAGR (3Y) – –
Operating cash flow growth (1Y) 29.2% –
Operating cash flow CAGR (3Y) – –
Free cash flow growth (1Y) 43.1% –
Free cash flow CAGR (3Y) – –

Profitability

14 metrics
MetricCONPAIYY
Gross margin 29.3% –
EBITDA margin 20.0% –
Operating margin 16.4% –
Pretax margin 11.7% –
Net margin 8.7% –
FCF margin 11.7% –
Operating cash flow margin 14.7% –
Return on equity 44.8% –
Return on assets 7.0% –
Return on invested capital 14.2% –
Return on capital employed 14.5% –
Asset turnover 0.8x –
Cash conversion (OCF / net income) 1.6x –
Stock comp / revenue 0.6% –

Financial Health

11 metrics
MetricCONPAIYY
Debt / assets 52.3% 28.2%
Debt / equity 3.2x -3.3x
Net debt / EBITDA 3.1x –
Debt / FCF 5.9x –
Liabilities / assets 83.9% 108.5%
Equity / assets 16.1% -8.5%
Interest coverage – –
Current ratio 1.4x –
Quick ratio 1.2x 0.3x
Cash ratio 0.4x 0.1x
Altman Z-score 2.56 –

Shareholder Returns

7 metrics
MetricCONPAIYY
Dividend yield 0.6% –
Net buyback yield 0.5% –
Shareholder yield 1.1% –
Payout ratio (earnings) 15.7% –
Payout ratio (FCF) 12.0% –
Dividend growth (1Y) 33.4% –
Dividend CAGR (3Y) – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCONPAIYY
Forward P/E 23.4xFY2026 –
EPS, next fiscal year $1.72FY2026 $-1.50FY2023
EPS growth, next FY +25.5%FY2026 –
EPS growth, the year after +10.5% –
Revenue, next fiscal year $2.30BFY2026 $89.98MFY2023
Revenue growth, next FY +6.3%FY2026 –
Revenue growth, the year after +3.1% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCONPAIYY
Held by institutions 87.3% –
Institutions holding 291 –
Change in shares held, QoQ +4.0% –
Institutions buying 166 –
Institutions selling 81 –
Buyers to sellers 2.05 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CONPAIYY
CON 1.00 -0.04
PAIYY -0.04 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CON and PAIYY?

Concentra Group Holdings Parent (CON) is the largest by market capitalisation: Concentra Group Holdings Parent (CON) $5.00B, Aesthetic Medical International Holdings (PAIYY) $491.09K.

Which stock has performed better?

Over the past year Concentra Group Holdings Parent (CON) returned the most: Concentra Group Holdings Parent (CON) +92.3%, Aesthetic Medical International Holdings (PAIYY) -95.2%. Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Concentra Group Holdings Parent (CON) 0.01%. Aesthetic Medical International Holdings (PAIYY) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Concentra Group Holdings Parent (CON) has been the steadiest (Concentra Group Holdings Parent (CON) 27.9%, Aesthetic Medical International Holdings (PAIYY) 421.9%). Volatility measures how widely the price swings, not the risk of the business.

Do CON and PAIYY move together?

Their daily returns over the past year have a correlation of -0.04, a negative relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, CON and PAIYY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Concentra Group Holdings Parent (CON) leads on 3. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.